GLP-1 Drugs and Fertility: What Every Woman on Ozempic or Mounjaro Must Know

Something I’m seeing more often in clinic doesn’t make it into most coverage of GLP-1 drugs: women with PCOS or obesity-related infertility who’ve been told for years that pregnancy would be difficult, starting semaglutide or tirzepatide for weight management, and becoming pregnant — sometimes before they’ve even registered that their cycles have normalized. This isn’t a side note. It’s a clinical pattern worth understanding in its own right, whether you’re trying to conceive or trying not to. Here’s what I actually tell patients.

The mechanism, briefly

Excess weight and insulin resistance raise insulin, which raises androgens, which suppresses or disrupts ovulation. GLP-1 therapy improves insulin sensitivity and reduces weight, androgen levels fall, and ovulation often resumes — sometimes for the first time in years. It’s the same underlying mechanism that makes bariatric surgery improve fertility; GLP-1 drugs produce a similar metabolic shift without surgery.

Six things worth knowing, each on its own

Restored ovulation catches people off guard. Many women with PCOS or irregular cycles have been told, or have assumed, that conception is unlikely. GLP-1-driven weight loss can restore regular ovulation within weeks to months — often before anyone realizes fertility status has actually changed.

The pill becomes less reliable on these drugs. GLP-1 medications slow gastric emptying, and oral contraceptives depend on consistent intestinal absorption. Both Novo Nordisk and Eli Lilly note this interaction in their own prescribing information. If you don’t want to conceive right now, an IUD or barrier method is more reliable than the pill alone while you’re on a GLP-1 drug.

These drugs are contraindicated in pregnancy, full stop. Animal studies show dose-dependent fetal harm; there’s no ethical way to study this directly in pregnant women, so the precautionary position is firm. If you discover you’re pregnant while on one, stop the medication immediately and contact your obstetrician and the manufacturer’s pregnancy registry.

Timing a planned pregnancy takes real advance planning. Reach your target weight loss before discontinuing — regain after stopping is common and can reverse the hormonal benefit you were counting on. Then stop at least two months before attempting conception (semaglutide’s half-life clears in about five weeks; two months gives a safety margin). Tirzepatide follows the same two-month rule.

This is not a fertility treatment. It doesn’t touch structural fertility issues, premature ovarian insufficiency, or male-factor infertility unrelated to metabolic health. What it treats is the metabolic root cause in a specific subset of women — real, but not universal.

Male fertility improves too, though the evidence is earlier-stage. Obesity is linked to lower testosterone and reduced sperm quality; weight loss through GLP-1 therapy improves both in obese men. Dedicated trials on male fertility outcomes specifically are still limited, but the early signal is genuinely encouraging.

The one piece of advice I want every patient to leave with

If you’re a woman of reproductive age on a GLP-1 drug and you don’t want to become pregnant right now, don’t rely on the pill alone — use an IUD or a reliable barrier method. If you are planning to conceive, work with your doctor to time the discontinuation properly rather than stopping abruptly or waiting until you’re already pregnant to think about it. Both directions of this — unexpected pregnancy and planned pregnancy — deserve a proactive conversation with your prescriber from day one, not an afterthought.